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Parkinson’s disease (PD) is the second most common neurodegenerative disorder,
affecting 1% of the population over age 60. In those patients cognitive dysfunction
is a persistent issue that impairs quality of life and productivity. Neuropathological
studies demonstrate significant damage in brain regions outside the nigral dopamine (DA)
system, including early degeneration of locus coeruleus norepinephrine (LC-NE) neurons,
yet discussion of PD and treatment focus has remained dopaminergic-based. Motor
symptoms benefit from DA replacement for many years, but other symptoms including
several cognitive deficits continue unabated. Recent interest in non-DA substrates of PD
highlights early involvement of LC-NE neurons and provides evidence for a prodromal
phase, with cognitive disturbance, even in sporadic PD. We outline insights from basic
research in LC-NE function to clinical and pathological evidence highlighting a role for NE in
PD cognitive dysfunction. We propose that loss of LC-NE regulation, particularly in higher
cortical regions, critically underlies certain cognitive dysfunctions in early PD. As a major
unmet need for patients, research and use of NE drugs in PD may provide significant
benefits for cognitive processing.
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Canonically, Parkinson’s disease (PD) is a neurodegenerative
movement disorder with progressive loss of substantia nigra (SN)
dopamine (DA) neurons that modulate cortical-striatal loops
(Hoehn and Yahr, 1967; Litvan et al., 2003; Dickson et al., 2009).
Accordingly, there is a long history of investigation and thera-
peutic development targeting DA replacement strategies for PD.
Products of this research have dramatically improved the man-
agement of many motor symptoms for PD patients, but DA
replacement has a complex interaction with cognitive symptoms
(Wolters, 2009; Barone, 2010; Kehagia et al., 2010a). The rela-
tive success in addressing motor symptoms in PD has highlighted
the paucity of validated treatments for non-motor symptoms,
including many cognitive dysfunctions. Studies in PD subpop-
ulations have identified a number of genetic variants associated
with known susceptibility or increased risk of PD (Dickson et al.,
2009). Studies of cognitive abilities in those individuals, and ret-
rospective studies in sporadic PD, demonstrate that cognitive
dysfunction can occur in pre-motor/prodromal stages of dis-
ease and is prevalent throughout disease progression, even in
patients who do not develop dementia (PDD; Halliday et al.,
2008; Leverenz et al., 2009; Keri et al., 2010). Cognitive dysfunc-
tion in early PD includes fronto-executive deficits with impair-
ments in planning, working memory, attentional control, and
cognitive flexibility; in contrast, PDD patients go on to develop
hallucinations as well as significant deficits in verbal and visu-
ospatial learning and memory (Kehagia et al., 2010a). Cognitive
symptoms in PD have significant impact on quality of life, life
expectancy, and caregiver stress (Diaz and Waters, 2009). The
presence of cognitive dysfunction in PD patients treated success-
fully for motor symptoms indicates the need for, and emergence
of, research into additional neural substrates of cognitive dysfunc-
tion in PD. Further study in genetically susceptible individuals,
and in early stages of sporadic PD, is warranted to develop
hypotheses on the progression of cognitive function in PD and
design interventional strategies to treat unmet needs in these
patients.
There are a number of non-DA neuropathological features in
PD, including significant loss of locus coeruleus norepinephrine
(LC-NE) and nucleus basalis of Meynert (nbM) cholinergic
(ACh) neurons (Braak et al., 2003; Halliday et al., 2006). Executive
functions, seated in the prefrontal cortex (PFC), rely on ascending
input from several neuromodulatory systems including DA, sero-
tonin, ACh, and prominently NE (Aston-Jones and Cohen, 2005;
Chudasama and Robbins, 2006; Robbins and Arnsten, 2009).
They are also regulated by SN-DA input to fronto-striatal loops
(Floresco and Jentsch, 2011), the loss of which is the pathologi-
cal hallmark of PD. Overt Lewy body pathology in PFC structures
occurs late in PD (Hawkes et al., 2010) andmay be associated with
PDD, as is nbM loss (Zweig et al., 1993). In contrast, early execu-
tive dysfunctions likely result from loss of PFC neuromodulation
from subcortical structures such as LC. Post-mortem analyses
from PD patients and MPTP models have identified reductions
in frontal NE and serotonin, but not in DA levels, highlighting
potential substrates for executive dysfunction in PD (Nayyar et al.,
2009; Goldstein et al., 2011). Within the CNS, Braak staging iden-
tifies a caudorostral progression of PD with Lewy pathology in
LC-NE neurons occurring before that in SN-DA or ACh popu-
lations. LC-NE pathology is posited to occur more than 10 years
before clinical diagnosis of PD (Braak et al., 2003; Hawkes et al.,
2010). During this period prodromal/early PD symptoms include
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2012 | Volume 6 | Article 48 | 1
BEHAVIORAL NEUROSCIENCE
Vazey and Aston-Jones Norepinephrine and cognition in Parkinson’s disease
functions classically associated with LC-NE such as mood and
sleep disturbances (Hawkes, 2008). We propose that the associ-
ated early executive dysfunction may be due, at least in part, to
LC-NE pathology as these cognitive deficits are independently
associated with LC-NE function in numerous animal studies
(Berridge and Waterhouse, 2003; Aston-Jones and Cohen, 2005).
LC-NE pathology/loss is thought to contribute to PD progres-
sion, occurring early and in advance of DA loss, and continuing
throughout PD (Mavridis et al., 1991; Gesi et al., 2000; Srinivasan
and Schmidt, 2003). Integrating cognitive studies on LC-NE func-
tion with PD pathology and animal models may identify novel
insights for early diagnosis and early interventions to improve
current therapeutic strategies. Below, we outline a growing body
of evidence from both clinical and preclinical investigations for a
potentially prominent yet underexplored role for LC-NE in cog-
nitive dysfunction of PD, specifically in measures of cognitive
inflexibility.
COGNITIVE FLEXIBILITY AND PD-RELATED COGNITIVE
INFLEXIBILITY
Adaptive cognitive function requires updating goals or strategies
to redirect attention when environmental or homeostatic con-
ditions dictate; i.e., cognitive flexibility. Coordinating efficient
behavioral execution of complex tasks by integrating goal and rule
representations with control processes, memories, and attention
is well established as an essential function of PFC (as reviewed in
Miller and Cohen, 2001; Aston-Jones and Cohen, 2005; Robbins
and Arnsten, 2009; Floresco and Jentsch, 2011). Deficits in cogni-
tive flexibility are a DA resistant hallmark of early PD that impacts
PD patients and their caregivers on a daily basis.
Lesion and imaging studies across species have strongly impli-
cated the PFC in the flexibility of cognitive processing (Miller
and Cohen, 2001; Kehagia et al., 2010b). Multiple paradigms
evaluate components of cognitive flexibility, from fundamental
rapid response inhibition to more complex set-shifting control
(Floresco and Jentsch, 2011). Set-shifting tasks are akin to the
classical Wisconsin Card Sorting Task (WCST), in which the
subject must sort each card into one of three categories based
on the face figures: shape, number, color. Once the subject has
learned the correct rule, the rule is changed without warning
and the subject must learn the new rule by trial and error. This
task reveals profound deficits in early PD, as well as other disor-
ders with PFC dysfunction (Lees and Smith, 1983; Owen et al.,
1993; Konishi et al., 1999). In set-shifting tasks, compound or
multi-dimensional stimuli are presented (e.g., shapes and over-
laid lines), and discrimination between stimuli in one dimen-
sion is required (e.g., shapes instead of lines). After acquiring
the discrimination rule, the rule changes unexpectedly requir-
ing a shift in attentional strategy to identify the new dimension
requiring attention (e.g., line direction). This is dependent on
not only suppression of a previously learned rule (e.g., square
shape) but also exploration of previously irrelevant stimuli or
dimensions (e.g., lines) and development of a new attentional
set (e.g., vertical lines denote correct stimulus). This strategy
change is termed an extra-dimensional shift (EDS) because atten-
tion to one dimension of stimuli (shapes) must be abandoned
and shifted to another (previously irrelevant) dimension (lines).
Neuropsychological assessments using set-shifting tasks such as
the WCST or CANTAB IED (intra-extra dimensional set shift)
tasks are now standard clinical practice for evaluating cognitive
flexibility. These evaluations have been translated into preclini-
cal set-shifting task (SST) analogs for rodents (Birrell and Brown,
2000; Ragozzino, 2002; Floresco et al., 2008). Imaging, lesion
and reversible inactivation studies across species have impli-
cated lateral PFC in particular (rodent mPFC) in EDS (Birrell
and Brown, 2000; Floresco et al., 2009). Early-stage PD patients
show relatively preserved performance in reversal learning and
intradimensional shifts (IDSs—changing discrimination strate-
gies within a dimension, e.g., square to circle) but are significantly
impaired in EDS (changing between dimensions, e.g., shape to
line; Downes et al., 1989; Owen et al., 1992). Basic neuroscience
work from several approaches indicates that NE regulation of
PFC is critical to attention and cognitive flexibility including
EDS in SST (Chudasama and Robbins, 2006; McGaughy et al.,
2008; Braver et al., 2009). Deficits in cognitive flexibility and
LC-NE pathology co-occur early in PD, and likely in prodromal
phases; the similar onset of LC pathology and cognitive inflex-
ibility in PD may indicate a link between this pathology and
symptom. In animal studies, LC-NE lesions directly produce PD-
like deficits in executive function, including cognitive inflexibility
(Tait et al., 2007; McGaughy et al., 2008). Until recently, EDS
deficits in PD had been postulated to be a consequence of DA
depletion in PFC or DAmis-regulation of cortico-striatal connec-
tions (Monchi et al., 2004; Nagano-Saito et al., 2008). In PD the
SN-DA neurons are affected whereas the predominant DAergic
input to PFC arises from the ventral tegmental area, a popula-
tion relatively spared in this disease (Hirsch et al., 1988; Braak
et al., 2004; Maingay et al., 2006). Neither L-dopa nor D1 ago-
nists restores EDS performance in PD patients, despite improving
motor function and cortical fMRI activity (Lange et al., 1992;
Jubault et al., 2009). This further indicates that non-DA sys-
tems are critically involved in PFC mediated flexibility deficits
in PD.
LC-NE SYSTEM AND COGNITIVE FLEXIBILITY
LC is the sole source of NE throughout cerebral cortex, and
projects especially to parietal, temporal, and frontal lobes (Foote
et al., 1983; Berridge and Waterhouse, 2003), areas prominently
involved in cognitive functions. Our lab found that LC neu-
rons in behaving animals exhibit two modes of activity, phasic
(short bursts of 8–10Hz spikes), and tonic (2–5Hz baseline
activity; Usher et al., 1999). These recording studies, in view of
associated behaviors and effects of NE on target neurons, led
Aston-Jones and Cohen (2005) to propose the Adaptive Gain
Theory, which states that the function of the two LC activ-
ity modes is to regulate the balance between exploitation of
known behavioral outcomes for a familiar strategy (phasic mode)
vs. exploration of possible new outcomes with a novel strat-
egy (e.g., flexible behavior, tonic mode), thereby maximizing
behavioral utility, i.e., response-related rewards. This and several
other prominent theories for LC function, including the Neural
Interrupt theory (Dayan and Yu, 2006), Reorienting System the-
ory (Corbetta et al., 2008), Network Reset theory (Bouret and
Sara, 2005), and State Modulation hypothesis (Berridge and
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Waterhouse, 2003), all converge in their attempts to identify
LC-NE output as a core element in the regulation of cognitive
flexibility.
LC-NE activity can cause rapid and complex responses
in cortical targets (Florin-Lechner et al., 1996; Berridge and
Abercrombie, 1999; Bouret and Sara, 2004). NE release increases
the gain of target cell activity, i.e., NE increases the responsiveness
of target cells to other inputs (Woodward et al., 1979; Servan-
Schreiber et al., 1990; Waterhouse et al., 1998). We have proposed
that this gain increase, occurring for a phasic LC response when
a decision has been reached, acts to boost processing in circuits
engaged by the decision, increasing task-related focus (Clayton
et al., 2004; Aston-Jones and Cohen, 2005). By doing this, pha-
sic LC responses are thought to promote task-related behavioral
responses (e.g., exploit known behavioral outcomes). However,
when behavioral success (utility) declines, LC neurons increase
tonic (baseline) activity and lose phasic, task-related responses.
As described in more detail elsewhere (Aston-Jones and Cohen,
2005), this tonic LC activity facilitates disengagement from a task
by temporally decoupling LC activity from task execution and
increasing the responsiveness of LC target neurons to non-task
related events (e.g., previously irrelevant dimensions), facilitating
exploration and behavioral flexibility.
Several studies show that LC-NE function is inextricably linked
to cognitive flexibility, particularly EDS performance (Tait et al.,
2007; McGaughy et al., 2008). In clinical studies, EDS ability is
impaired early in PD, when LC-NE neurons are lost (Chan-Palay
and Asan, 1989; Petrovitch et al., 2011). Preclinically, atipame-
zole, an NE α2 antagonist that increases NE release, improves
EDS shifting in a manner blocked by local mPFC α1 antago-
nists (Lapiz and Morilak, 2006). Desipramine, a NE reuptake
blocker, also improves EDS performance and increases extracel-
lular NE release in mPFC during set shifting, particularly when
given chronically (Lapiz et al., 2007). Recently, the specific NE
reuptake inhibitor atomoxetine (ATM) was shown to rescue EDS
deficits elicited by selective lesions (via DBH saporin toxin) of
LC-NE fibers in rat mPFC (Newman et al., 2008). The EDS
deficits produced by these lesions concur with those produced by
neurochemically specific (6-OHDA) lesions of the dorsal nora-
drenergic bundle (DNAB) of LC-NE projections to forebrain
(Tait et al., 2007; McGaughy et al., 2008). The intersection of
conclusions from behavioral neurophysiology studies in animals
showing a role for LC in exploration and behavioral flexibil-
ity (described above) with these from animal studies of LC
lesions strongly supports the view that LC-NE plays an impor-
tant role in cognitive flexibility. We propose that when task utility
declines, tonic activity increases in LC neurons, which increases
gain (synaptic responsivity) throughout the CNS at widespread
LC targets. This tonic and widespread gain increase facilitates
activity in non-task-related circuits and thereby augments tran-
sitions among representations for other tasks or rules (i.e.,
increases exploratory behavior and cognitive flexibility). In PD,
we hypothesize that degeneration of LC-NE neurons dampens
the NE-mediated modulation needed to disrupt the ongoing task
and augment competing circuits, in effect inhibiting task dis-
engagement and flexible behavior and promoting perseverative
responding.
LC-NE AS A THERAPEUTIC TARGET FOR PD
NE modulation is a viable therapeutic target in PD due to the
proven safety and efficacy of NE modulators in other disor-
ders, early involvement of LC in PD neuropathology, opportunity
for concurrent efficacy in other non-motor symptoms (depres-
sion, sleep disorders) as well as potential impact on disease
progression (as reviewed by Fornai et al., 2007; Rommelfanger
and Weinshenker, 2007). A number of small trials have shown
improvements in DA replacement therapy side effects and non-
motor symptoms with therapies that target NE (Carpentier et al.,
1996; Bedard et al., 1998; Rascol et al., 2001; Pintor et al., 2006;
Jankovic, 2009). In relation to cognitive function only a few small
trials directly investigating NE replacement have been undertaken
in PD patients. The specific NE reuptake inhibitor ATM led to
improvements in clinical global impression scales of cognition in
two recent studies (Marsh et al., 2009; Weintraub et al., 2010).
Cognitive flexibility was not examined in those studies, but in
preclinical reports ATM improved EDS deficits produced by spe-
cific LC-NE lesions in PFC (Newman et al., 2008). Evidence of
pathology in the LC-NE system in vivo and preclinical studies
described above identify unanswered questions on a possible role
for LC-NE neuromodulation in early PD cognitive dysfunction.
Can the preclinical role of LC-NE in behavioral flexibility trans-
late into a viable therapeutic target for PD? Only future studies of
NEmodulation onmeasures of cognitive flexibility in PD patients
can answer this, and such studies would provide valuable addi-
tions to our understanding of PD pathology and the role of NE in
cognitive processing.
LC-NE INTERACTIONSWITH DA AND ACh IN PD
COGNITIVE INFLEXIBILITY
PD pathology encompasses many systems that contribute to
various cognitive impairments. Widespread DA loss is the fun-
damental pathology of PD, but evidence for a role of striatal DA
in cognitive flexibility is inconclusive (Collins et al., 2000; Jubault
et al., 2009); thismay be due to compensatorymechanisms in PFC
following loss of striatal DA regulation. 6-OHDA lesions of mar-
moset PFC led to cortical-subcortical DA imbalance and impaired
initial task acquisition, but did not impair reversal or EDS per-
formance; in fact, by disrupting maintenance of the attentional
set these lesions appeared to improve EDS (Roberts et al., 1994;
Crofts et al., 2001). Local antagonism of D1 or D2 transmission
in mPFC causes mild impairments in set-shifting, but local infu-
sions of D1 or D2 agonists in mPFC of rodents do not affect SST
(Floresco et al., 2006). These findings are similar to clinical stud-
ies where DA-based treatments for PD do not improve cognitive
flexibility but may be more important in other PD related execu-
tive impairments such as planning and spatial working memory
(Jubault et al., 2009; Kehagia et al., 2010a).
Of note in relation to cognitive dysfunction in PD is nbM
degeneration. Because LC-NE innervation activates nbM ACh
neurons, LC-NE pathology early in PD may contribute to
decreased cortical ACh levels and subsequent cholinergic dys-
function in PD (Jones, 2004; Calabresi et al., 2006; Espana and
Berridge, 2006). Ascending progression of Lewy body pathol-
ogy with degeneration in nbM ACh neurons occurs in many PD
patients, and is more pronounced with PDD, the severity may
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be a contributing factor in the development of PDD (Bohnen
et al., 2003; Hilker et al., 2005; Jellinger, 2006). Concurrent use
of cholinergic inhibitors also contributes to cognitive decline and
development of dementia in PD patients, whereas cholinesterase
inhibitors can provide significant benefits for patients with PDD
(Ehrt et al., 2010; Kehagia et al., 2010a). Performance on semantic
fluency tests (dependent on posterior cortical integrity as opposed
to PFC functions) are also strong predictors of progression to
PDD, demonstrating a separation of NE- and ACh-dependent
aspects of cognitive processing in early PD vs. PDD, respectively
(Williams-Gray et al., 2007). Evidence for cholinergic involve-
ment specifically in cognitive flexibility as part of the early pro-
dromal dysexecutive phenotype in PD is limited; in fact, ACh
denervation has been shown to have no effect on EDS perfor-
mance (Robbins and Roberts, 2007; McGaughy et al., 2008). It
appears ACh has a significant role in cognitive processing in PD,
but that it is more pertinent to later stages of PD with the develop-
ment of PDD; also, cholinergic function in PD may be influenced
by loss of ascending LC-NE input.
FOCUS ON THE LOCUS: LOSS OF LC-NE NEURONS AND
COGNITIVE IMPAIRMENT IN EARLY PD
Evidence is increasing for an important role of LC in multi-
ple neurodegenerative disorders, including PD (German et al.,
1992; Gesi et al., 2000; Weinshenker, 2008). We and others have
argued that LC has a number of functions besides its roles in
cognitive processing, including regulation of sleep, mood, and
neuroinflammation, all of which are perturbed in PD and may
benefit from NE-based therapies (Aston-Jones and Bloom, 1981;
Aston-Jones et al., 1996; Gonzalez and Aston-Jones, 2008; Heneka
et al., 2010). Until now, LC loss in PD has primarily been investi-
gated for contributing to nigral DA neuron death, exacerbating
motor dysfunction and dyskinesias (Srinivasan and Schmidt,
2003; Fulceri et al., 2007; Rommelfanger et al., 2007). In indi-
viduals with a genetic predisposition to PD, cognitive flexibility
deficits have been identified up to 5 years prior to onset of
motor symptoms (Keri et al., 2010). In idiopathic PD, cognitive
dysfunction is commonly present below Hoehn and Yahr Stage
2 and prevails throughout disease progression, even in advanced
patients who do not develop full dementia (Downes et al., 1989;
Green et al., 2002; Rodriguez-Ferreiro et al., 2010). Very little has
been done to incorporate basic research on LC-NE in cognition
with the corresponding cognitive impairment and neuropathol-
ogy in PD. As discussed above, several animal studies find that
depleted NE in PFC results in poor EDS performance, and that
this impairment is resolved by manipulations that increase NE
transmission (Tait et al., 2007; Newman et al., 2008).
CONCLUDING PERSPECTIVE
PD is characteristically a dopaminergic disorder but DA resistant
non-motor symptoms, including dysexecutive features appear
early if not in prodromal phases of PD. As prefrontal DA lev-
els are largely preserved throughout PD, other systems are likely
substrates. It is postulated that LC-NE pathology also begins
early in PD progression. Involvement of LC-NE system has been
recognized as part of PD neuropathology with Lewy body accu-
mulation, reductions prefrontal NE levels, and loss of LC neurons.
The role LC-NE pathology plays in PD, particularly in cogni-
tive processing, is underexplored and only beginning to emerge.
We propose that loss of prefrontal NE input may contribute to
executive dysfunction and specifically EDS deficits early in PD.
We know from extensive preclinical investigation that prefrontal
LC-NE projections have a critical role in executive function, par-
ticularly mechanisms underlying EDS. Currently there are gaps
between our understanding of LC-NE function and application
of NE targeted therapies in PD research and treatment. Future
studies directly investigating the potential role of LC-NE in exec-
utive function in PD could lead to novel therapies and insight into
LC-NE in cognitive processing and pathological processes in PD.
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